{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T14:46:48Z","timestamp":1787237208768,"version":"build-2736575974"},"reference-count":61,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,11,8]],"date-time":"2023-11-08T00:00:00Z","timestamp":1699401600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Sleep Medicine: X"],"published-print":{"date-parts":[[2023,12]]},"DOI":"10.1016\/j.sleepx.2023.100094","type":"journal-article","created":{"date-parts":[[2023,11,19]],"date-time":"2023-11-19T10:31:38Z","timestamp":1700389898000},"page":"100094","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"special_numbering":"C","title":["Effects of new hypnotic drugs on cognition: A systematic review and network meta-analysis"],"prefix":"10.1016","volume":"6","author":[{"given":"Mengzhen","family":"Zhou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rujia","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiyou","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shi","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.sleepx.2023.100094_bib1","series-title":"BCPP, FASHP, insomnia overview: epidemiology, pathophysiology, diagnosis and monitoring, and nonpharmacologic therapy","author":"Julie","year":"2020"},{"issue":"1","key":"10.1016\/j.sleepx.2023.100094_bib2","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.jsmc.2019.10.002","article-title":"Insomnia and cognitive performance","volume":"15","author":"Brownlow","year":"2020","journal-title":"Sleep Med Clin"},{"key":"10.1016\/j.sleepx.2023.100094_bib3","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1159\/000514965","article-title":"The insomnia-addiction positive feedback loop: role of the orexin system","volume":"45","author":"Fragale","year":"2021","journal-title":"Front Neurol Neurosci"},{"key":"10.1016\/j.sleepx.2023.100094_bib4","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.yfrne.2017.02.004","article-title":"Sleep and hippocampal neurogenesis: implications for Alzheimer's disease","volume":"45","author":"Kent","year":"2017","journal-title":"Front Neuroendocrinol"},{"issue":"1","key":"10.1016\/j.sleepx.2023.100094_bib5","doi-asserted-by":"crossref","first-page":"e6","DOI":"10.2146\/ajhp160381","article-title":"Benzodiazepine use and cognitive decline in the elderly","volume":"75","author":"Picton","year":"2018","journal-title":"Am J Health Syst Pharm"},{"key":"10.1016\/j.sleepx.2023.100094_bib6","doi-asserted-by":"crossref","first-page":"g5205","DOI":"10.1136\/bmj.g5205","article-title":"Benzodiazepine use and risk of Alzheimer's disease: case-control study","volume":"349","author":"Billioti de Gage","year":"2014","journal-title":"BMJ"},{"key":"10.1016\/j.sleepx.2023.100094_bib7","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1007\/7854_2015_425","article-title":"Benzodiazepines","volume":"34","author":"Nielsen","year":"2017","journal-title":"Curr Top Behav Neurosci"},{"issue":"3","key":"10.1016\/j.sleepx.2023.100094_bib8","doi-asserted-by":"crossref","DOI":"10.1093\/sleep\/zsz238","article-title":"Biphasic feature of placebo response in primary insomnia: pooled analysis of data from randomized controlled clinical trials of orexin receptor antagonists","volume":"43","author":"He","year":"2020","journal-title":"Sleep"},{"issue":"5","key":"10.1016\/j.sleepx.2023.100094_bib9","doi-asserted-by":"crossref","DOI":"10.3390\/cells10051161","article-title":"Berberine improves cognitive impairment by simultaneously impacting cerebral blood flow and beta-amyloid accumulation in an APP\/tau\/PS1 mouse model of alzheimer's disease","volume":"10","author":"Ye","year":"2021","journal-title":"Cells"},{"issue":"1","key":"10.1016\/j.sleepx.2023.100094_bib10","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1038\/s41386-019-0478-5","article-title":"Bidirectional relationship between sleep and Alzheimer's disease: role of amyloid, tau, and other factors","volume":"45","author":"Wang","year":"2020","journal-title":"Neuropsychopharmacology"},{"issue":"9821","key":"10.1016\/j.sleepx.2023.100094_bib11","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1016\/S0140-6736(11)60750-2","article-title":"Chronic insomnia","volume":"379","author":"Morin","year":"2012","journal-title":"The Lancet"},{"issue":"1","key":"10.1016\/j.sleepx.2023.100094_bib12","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1097\/NMD.0000000000001074","article-title":"Zolpidem-associated consequences: an updated literature review with case reports","volume":"208","author":"Westermeyer","year":"2020","journal-title":"J Nerv Ment Dis"},{"key":"10.1016\/j.sleepx.2023.100094_bib13","series-title":"Goa adis international limited, A., New Zealand, zolpidem an update of its pharmacology, therapeutic efficacy and tolerability in the treatment of insomnia","author":"Holm","year":"2000"},{"issue":"4","key":"10.1016\/j.sleepx.2023.100094_bib14","doi-asserted-by":"crossref","DOI":"10.1111\/jsr.13071","article-title":"Zolpidem overutilisation among Korean patients with insomnia","volume":"29","author":"Kim","year":"2020","journal-title":"J Sleep Res"},{"key":"10.1016\/j.sleepx.2023.100094_bib15","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1016\/B978-0-12-397220-0.00011-8","article-title":"Zolpidem tartrate","volume":"37","author":"Foda","year":"2012","journal-title":"Profiles Drug Subst Excipients Relat Methodol"},{"key":"10.1016\/j.sleepx.2023.100094_bib16","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1159\/000514960","article-title":"Sleep, orexin and cognition","volume":"45","author":"Toor","year":"2021","journal-title":"Front Neurol Neurosci"},{"issue":"3","key":"10.1016\/j.sleepx.2023.100094_bib17","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1007\/s00429-021-02447-w","article-title":"Orexin A peptidergic system: comparative sleep behavior, morphology and population in brains between wild type and Alzheimer's disease mice","volume":"227","author":"Zhao","year":"2022","journal-title":"Brain Struct Funct"},{"issue":"11","key":"10.1016\/j.sleepx.2023.100094_bib18","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1016\/j.tins.2021.09.002","article-title":"Orexin (hypocretin) and addiction","volume":"44","author":"Mehr","year":"2021","journal-title":"Trends Neurosci"},{"issue":"5","key":"10.1016\/j.sleepx.2023.100094_bib19","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1016\/j.conb.2013.04.007","article-title":"Orexin deficiency and narcolepsy","volume":"23","author":"Sakurai","year":"2013","journal-title":"Curr Opin Neurobiol"},{"issue":"2","key":"10.1016\/j.sleepx.2023.100094_bib20","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1177\/0004867417747402","article-title":"Suvorexant for the treatment of insomnia in patients with Alzheimer's disease","volume":"52","author":"Hamuro","year":"2018","journal-title":"Aust N Z J Psychiatr"},{"issue":"6","key":"10.1016\/j.sleepx.2023.100094_bib21","doi-asserted-by":"crossref","DOI":"10.1093\/sleep\/zsaa278","article-title":"Animal models of narcolepsy and the hypocretin\/orexin system: past, present, and future","volume":"44","author":"Tisdale","year":"2021","journal-title":"Sleep"},{"key":"10.1016\/j.sleepx.2023.100094_bib22","doi-asserted-by":"crossref","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"issue":"4","key":"10.1016\/j.sleepx.2023.100094_bib23","doi-asserted-by":"crossref","DOI":"10.1093\/sleep\/zsy260","article-title":"On-the-road driving performance the morning after bedtime administration of lemborexant in healthy adult and elderly volunteers","volume":"42","author":"Vermeeren","year":"2019","journal-title":"Sleep"},{"issue":"3","key":"10.1016\/j.sleepx.2023.100094_bib24","doi-asserted-by":"crossref","first-page":"489","DOI":"10.5665\/sleep.3482","article-title":"Residual effects of low-dose sublingual zolpidem on highway driving performance the morning after middle-of-the-night use","volume":"37","author":"Vermeeren","year":"2014","journal-title":"Sleep"},{"issue":"1\u20133","key":"10.1016\/j.sleepx.2023.100094_bib25","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/j.schres.2014.10.002","article-title":"The impact of eszopiclone on sleep and cognition in patients with schizophrenia and insomnia: a double-blind, randomized, placebo-controlled trial","volume":"160","author":"Tek","year":"2014","journal-title":"Schizophr Res"},{"key":"10.1016\/j.sleepx.2023.100094_bib26","series-title":"A phase II dose-ranging study evaluating the efficacy and safety of the orexin receptor antagonist filorexant (MK-6096) in patients with primary insomnia","author":"Connor","year":"2016"},{"issue":"2","key":"10.1016\/j.sleepx.2023.100094_bib27","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1179\/0886963414Z.00000000084","article-title":"Efficacy of treatment of insomnia in migraineurs with eszopiclone (Lunesta(R)) and its effect on total sleep time, headache frequency, and daytime functioning: a randomized, double-blind, placebo-controlled, parallel-group, pilot study","volume":"33","author":"Spierings","year":"2015","journal-title":"Cranio"},{"issue":"21","key":"10.1016\/j.sleepx.2023.100094_bib28","doi-asserted-by":"crossref","first-page":"e2222","DOI":"10.1212\/WNL.0000000000009475","article-title":"Daridorexant, a new dual orexin receptor antagonist, in elderly subjects with insomnia disorder","volume":"94","author":"Zammit","year":"2020","journal-title":"Neurology"},{"issue":"2","key":"10.1016\/j.sleepx.2023.100094_bib29","first-page":"259","article-title":"Effects of suvorexant, an orexin receptor antagonist, on sleep parameters as measured by polysomnography in healthy men","volume":"36","author":"Sun","year":"2013","journal-title":"Sleep"},{"issue":"4","key":"10.1016\/j.sleepx.2023.100094_bib30","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1097\/JCP.0000000000001439","article-title":"Effects of bedtime dosing with suvorexant and zolpidem on balance and psychomotor performance in healthy elderly participants during the night and in the morning","volume":"41","author":"Bland","year":"2021","journal-title":"J Clin Psychopharmacol"},{"issue":"2","key":"10.1016\/j.sleepx.2023.100094_bib31","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1038\/s41386-021-01191-3","article-title":"The efficacy and safety of zolpidem and zopiclone to treat insomnia in Alzheimer's disease: a randomized, triple-blind, placebo-controlled trial","volume":"47","author":"Louzada","year":"2022","journal-title":"Neuropsychopharmacology"},{"issue":"11","key":"10.1016\/j.sleepx.2023.100094_bib32","doi-asserted-by":"crossref","first-page":"1708","DOI":"10.1002\/mds.23168","article-title":"Treatment of insomnia in Parkinson's disease: a controlled trial of eszopiclone and placebo","volume":"25","author":"Menza","year":"2010","journal-title":"Mov Disord"},{"issue":"9","key":"10.1016\/j.sleepx.2023.100094_bib33","doi-asserted-by":"crossref","DOI":"10.1093\/sleep\/zsaa123","article-title":"Long-term efficacy and tolerability of lemborexant compared with placebo in adults with insomnia disorder: results from the phase 3 randomized clinical trial SUNRISE 2","volume":"43","author":"Karppa","year":"2020","journal-title":"Sleep"},{"issue":"10","key":"10.1016\/j.sleepx.2023.100094_bib34","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.5665\/SLEEP.1272","article-title":"Next-day effects of ramelteon (8 mg), zopiclone (7.5 mg), and placebo on highway driving performance, memory functioning, psychomotor performance, and mood in healthy adult subjects","volume":"34","author":"Mets","year":"2011","journal-title":"Sleep"},{"issue":"1","key":"10.1016\/j.sleepx.2023.100094_bib35","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1186\/1744-859X-11-15","article-title":"Effects of eszopiclone on safety, subjective measures of efficacy, and quality of life in elderly and nonelderly Japanese patients with chronic insomnia, both with and without comorbid psychiatric disorders: a 24-week, randomized, double-blind study","volume":"11","author":"Uchimura","year":"2012","journal-title":"Ann Gen Psychiatr"},{"issue":"10","key":"10.1016\/j.sleepx.2023.100094_bib36","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1016\/j.sleep.2012.08.015","article-title":"A randomized placebo-controlled polysomnographic study of eszopiclone in Japanese patients with primary insomnia","volume":"13","author":"Uchimura","year":"2012","journal-title":"Sleep Med"},{"issue":"8","key":"10.1016\/j.sleepx.2023.100094_bib37","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.5665\/sleep.1996","article-title":"The orexin antagonist SB-649868 promotes and maintains sleep in men with primary insomnia","volume":"35","author":"Bettica","year":"2012","journal-title":"Sleep"},{"issue":"5","key":"10.1016\/j.sleepx.2023.100094_bib38","doi-asserted-by":"crossref","first-page":"765","DOI":"10.5664\/jcsm.8294","article-title":"Safety of lemborexant versus placebo and zolpidem: effects on auditory awakening threshold, postural stability, and cognitive performance in healthy older participants in the middle of the night and upon morning awakening","volume":"16","author":"Murphy","year":"2020","journal-title":"J Clin Sleep Med"},{"issue":"11","key":"10.1016\/j.sleepx.2023.100094_bib39","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.5664\/jcsm.6800","article-title":"Lemborexant, A dual orexin receptor antagonist (DORA) for the treatment of insomnia disorder: results from a bayesian, adaptive, randomized, double-blind, placebo-controlled study","volume":"13","author":"Murphy","year":"2017","journal-title":"J Clin Sleep Med"},{"issue":"8","key":"10.1016\/j.sleepx.2023.100094_bib40","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1177\/0269881112448946","article-title":"Orexin receptor antagonism: an ascending multiple-dose study with almorexant","volume":"26","author":"Hoever","year":"2012","journal-title":"J Psychopharmacol"},{"issue":"3","key":"10.1016\/j.sleepx.2023.100094_bib41","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1097\/JCP.0b013e31828f5a7a","article-title":"Tolerability, pharmacokinetics, and pharmacodynamics of single-dose almorexant, an orexin receptor antagonist, in healthy elderly subjects","volume":"33","author":"Hoever","year":"2013","journal-title":"J Clin Psychopharmacol"},{"key":"10.1016\/j.sleepx.2023.100094_bib42","series-title":"A 12-week, randomized, double-blind, placebo-controlled study evaluating the effect of eszopiclone 2 mg on sleep\/wake function in older adults with primary and comorbid insomnia","author":"Sonia Ancoli-Israel","year":"2010"},{"issue":"4","key":"10.1016\/j.sleepx.2023.100094_bib43","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1111\/j.1365-2869.2009.00746.x","article-title":"Highway driving performance and cognitive functioning the morning after bedtime and middle-of-the-night use of gaboxadol, zopiclone and zolpidem","volume":"18","author":"Leufkens","year":"2009","journal-title":"J Sleep Res"},{"issue":"14","key":"10.1016\/j.sleepx.2023.100094_bib44","first-page":"2785","article-title":"Residual effects of zopiclone 7.5 mg on highway driving performance in insomnia patients and healthy controls: a placebo controlled crossover study","volume":"231","author":"Leufkens","year":"2014","journal-title":"Psychopharmacology (Berl)"},{"issue":"2","key":"10.1016\/j.sleepx.2023.100094_bib45","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.biopsych.2014.10.003","article-title":"Suvorexant in patients with insomnia: results from two 3-month randomized controlled clinical trials","volume":"79","author":"Herring","year":"2016","journal-title":"Biol Psychiatr"},{"issue":"7","key":"10.1016\/j.sleepx.2023.100094_bib46","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1016\/j.jagp.2017.03.004","article-title":"Suvorexant in elderly patients with insomnia: pooled analyses of data from phase III randomized controlled clinical trials","volume":"25","author":"Herring","year":"2017","journal-title":"Am J Geriatr Psychiatr"},{"issue":"10","key":"10.1016\/j.sleepx.2023.100094_bib47","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1016\/j.sleep.2013.04.010","article-title":"Alertness and psychomotor performance effects of the histamine-3 inverse agonist MK-0249 in obstructive sleep apnea patients on continuous positive airway pressure therapy with excessive daytime sleepiness: a randomized adaptive crossover study","volume":"14","author":"Herring","year":"2013","journal-title":"Sleep Med"},{"key":"10.1016\/j.sleepx.2023.100094_bib48","series-title":"Orexin receptor antagonism for treatment of insomnia","author":"Joseph Herring","year":"2012"},{"issue":"9","key":"10.1016\/j.sleepx.2023.100094_bib49","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.5664\/jcsm.6116","article-title":"Suvorexant in patients with insomnia: pooled analyses of three-month data from phase-3 randomized controlled clinical trials","volume":"12","author":"Herring","year":"2016","journal-title":"J Clin Sleep Med"},{"issue":"3","key":"10.1016\/j.sleepx.2023.100094_bib50","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1002\/ana.25680","article-title":"Daridorexant, a new dual orexin receptor antagonist to treat insomnia disorder","volume":"87","author":"Dauvilliers","year":"2020","journal-title":"Ann Neurol"},{"issue":"37","key":"10.1016\/j.sleepx.2023.100094_bib51","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000012383","article-title":"Cognitive behavioral therapy for insomnia combined with eszopiclone for the treatment of sleep disorder patients transferred out of the intensive care unit: a single-centred retrospective observational study","volume":"97","author":"Zhang","year":"2018","journal-title":"Medicine (Baltimore)"},{"issue":"1","key":"10.1016\/j.sleepx.2023.100094_bib52","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0084590","article-title":"Cognitive reserve in young and old healthy subjects: differences and similarities in a testing-the-limits paradigm with DSST","volume":"9","author":"Zihl","year":"2014","journal-title":"PLoS One"},{"issue":"2","key":"10.1016\/j.sleepx.2023.100094_bib53","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1093\/ijnp\/pyx070","article-title":"A network meta-analysis comparing effects of various antidepressant classes on the Digit Symbol substitution test (DSST) as a measure of cognitive dysfunction in patients with major depressive disorder","volume":"21","author":"Baune","year":"2018","journal-title":"Int J Neuropsychopharmacol"},{"issue":"9","key":"10.1016\/j.sleepx.2023.100094_bib54","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1089\/cap.2016.0206","article-title":"Suvorexant for the treatment of insomnia in adolescents","volume":"27","author":"Kawabe","year":"2017","journal-title":"J Child Adolesc Psychopharmacol"},{"issue":"1","key":"10.1016\/j.sleepx.2023.100094_bib55","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1111\/adb.12507","article-title":"Suvorexant, an orexin\/hypocretin receptor antagonist, attenuates motivational and hedonic properties of cocaine","volume":"23","author":"Gentile","year":"2018","journal-title":"Addiction Biol"},{"key":"10.1016\/j.sleepx.2023.100094_bib56","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.smrv.2016.09.004","article-title":"Suvorexant for the treatment of primary insomnia: a systematic review and meta-analysis","volume":"35","author":"Kuriyama","year":"2017","journal-title":"Sleep Med Rev"},{"key":"10.1016\/j.sleepx.2023.100094_bib57","series-title":"Sleep medicine: insomnia and sleep","author":"Bollu","year":"2019"},{"issue":"4","key":"10.1016\/j.sleepx.2023.100094_bib58","doi-asserted-by":"crossref","DOI":"10.1093\/sleep\/zsz016","article-title":"Sleep deprivation differentially affects subcomponents of cognitive control","volume":"42","author":"Kusztor","year":"2019","journal-title":"Sleep"},{"issue":"5","key":"10.1016\/j.sleepx.2023.100094_bib59","doi-asserted-by":"crossref","DOI":"10.1093\/sleep\/zsy025","article-title":"Sleep deprivation and cerebrospinal fluid biomarkers for Alzheimer's disease","volume":"41","author":"Olsson","year":"2018","journal-title":"Sleep"},{"issue":"1","key":"10.1016\/j.sleepx.2023.100094_bib60","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1159\/000445831","article-title":"The impact of mild cognitive impairment on gait and balance: a systematic review and meta-analysis of studies using instrumented assessment","volume":"63","author":"Bahureksa","year":"2017","journal-title":"Gerontology"},{"issue":"2","key":"10.1016\/j.sleepx.2023.100094_bib61","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.pharep.2015.09.002","article-title":"Emerging role of orexin antagonists in insomnia therapeutics: an update on SORAs and DORAs","volume":"68","author":"Kumar","year":"2016","journal-title":"Pharmacol Rep"}],"container-title":["Sleep Medicine: X"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2590142723000344?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2590142723000344?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,12]],"date-time":"2025-11-12T02:27:13Z","timestamp":1762914433000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2590142723000344"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12]]},"references-count":61,"alternative-id":["S2590142723000344"],"URL":"https:\/\/doi.org\/10.1016\/j.sleepx.2023.100094","relation":{},"ISSN":["2590-1427"],"issn-type":[{"value":"2590-1427","type":"print"}],"subject":[],"published":{"date-parts":[[2023,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Effects of new hypnotic drugs on cognition: A systematic review and network meta-analysis","name":"articletitle","label":"Article Title"},{"value":"Sleep Medicine: X","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.sleepx.2023.100094","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Author(s). Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"100094"}}